12085 Research Drive
203 articles about Oragenics, Inc.
Oragenics, Inc. to Present Data from Its Lantibiotics Program at the Boulder Peptide Symposium Monday, September 24, 2018
Oragenics, Inc. today announced that Dr. Martin Handfield will present data on its lantibiotics program for the treatment of serious and prevalent infectious diseases at the Boulder Peptide Symposium.
Oragenics, Inc. Resumes Phase 2 Clinical Trial of AG013 in Oral Mucositis Following Positive Routine Safety Review
AG013 is a live biotherapeutic product for the potential treatment of OM following a positive review by an independent Data Safety Monitoring Board (DSMB).
Oragenics, Inc. Announces Closing of $13.8 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
Oragenics, Inc. announced the closing of an underwritten public offering of units for gross proceeds of approximately $13.8 million
Oragenics, Inc. Announces Pricing of $12 Million Underwritten Public Offering
Oragenics, Inc. announced the pricing of an underwritten public offering of units for gross proceeds of $12 million, prior to deducting underwriting discounts and commissions and offering expenses payable by the Company.
Diamond Equity Research Initiates Coverage on Oragenics Inc. (NYSE:OGEN) with a Valuation of $3.50 Per Share
Diamond Equity Research has initiated coverage of Oragenics Inc.
Oragenics, Inc. Announces Peer-Reviewed Publication Detailing Discovery of OG716 for C. difficile infections
Oragenics Reports Positive Interim Safety Analysis Results from Its Phase 2 Clinical Trial of AG013 for Oral Mucositis
Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), today announced positive results from its interim safety analysis as requested by FDA on patients from its Phase 2 clinical trial of AG013 for the treatment of OM.
Oragenics, Inc. Announces Pricing of $1.8 Million Registered Direct Offering
Oragenics, Inc. announced that it has entered into a securities purchase agreement with certain new institutional investors providing for the purchase and sale of 900,000 shares of common stock at a price of $2.00 per share in a registered direct offering.
Oragenics, Inc. Announces Peer Reviewed Publication Examining Efficacy of Mutacin 1140 Lantibiotic Variants against Clostridium difficile
Researchers sought to identify a lead candidate for the treatment of Clostridium difficile (C. difficile) infections based on the lantibiotic Mutacin 1140.
Oragenics, Inc. Announces Reverse Stock Split Effective January 19, 2018
The Company’s common stock will begin trading on a split-adjusted basis when the markets open on January 22, 2018 under the existing trading symbol “OGEN”.
Oragenics Regains Compliance With NYSE American Continued Listing Standards
In a letter dated November 10, 2017, the Exchange notified the Company that it had successfully regained compliance with the NYSE American continued listing standards.
Oragenics Announces Closing of $3.3 Million Preferred Stock Private Placement and $3.4 Million Debt Conversion into Equity
Oragenics today announced that it has completed a private placement of $3.3 million of Non-Voting Series B Convertible Preferred Stock with four existing shareholders who are accredited investors including an entity affiliated with a director of the Company. Concurrently with the Preferred Stock Financing
Oragenics Doses First Patient In Phase II Clinical Trial Of AG013 For Oral Mucositis
Oragenics Announces Completion Of Second Closing Of $3.0 Million Preferred Stock Private Placement
Oragenics Announces Notification Of Noncompliance With Additional NYSE MKT Continued Listing Standard
Oragenics Presents Development Of Novel Lantibiotic Against Clostridium Difficile At The ICAAC Conference
Oragenics Announces $3.0 Million Preferred Stock Private Placement And $2.4 Million Loan
Oragenics Provides First Quarter 2017 Update
Oragenics Receives Audit Opinion With Going Concern Explanation
Oragenics Shareholder Update